Vertaling van "treatment trial " (Nederlands → Frans) :

L, et al. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study.
L, et al. Single-center trials show larger treatment effects than multicenter trials: evidence from a metaepidemiologic study.

The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).JAMA 2002; 288: 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstline antihypertensive therapies : a meta-analysis of randomised controlled trials.
The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstlineantihypertensive therapies : a meta-analysis of randomised controlled trials.

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.

Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
DOI : 10.1002/ 14651858.CD008143.pub2. Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

De " Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial " (ALLHAT-studie).
L’" Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (l’étude ALLHAT).

32.Sano M , Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease.
32. Sano M , Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease.

Lancet 363, 2022- 2031 (2004) M.A. Weber et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial.
Lancet 363, 2022-2031 (2004) M.A. Weber et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial.

Het was voorzien om in dit nummer van de Folia de ALLHAT-studie (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) te bespreken.
Il était prévu de discuter dans ce numéro de l’étude ALLHAT (Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial), mais étant donné la publication récente de nouvelles données concernant le traitement initial de l’hypertension artérielle, cette discussion est postposée aux Folia d’avril 2003 [voir aussi la rubrique « Bon à savoir » sur notre site internet].

De ALLHAT-studie 1 (Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial) was een gerandomiseerde dubbelblinde studie waarin de doeltreffendheid van lisinopril, amlodipine en chloortalidon vergeleken werd.
L’étude ALLHAT 1 (Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial) est une étude randomisée en double aveugle dans laquelle l’efficacité du lisinopril, de l’amlodipine et de la chlortalidone ont été comparées.

De ALLHAT-studie (1) (Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial) was een gerandomiseerde dubbelblinde studie waarin de doeltreffendheid van lisinopril, amlodipine en chloortalidon vergeleken werd.
L'étude ALLHAT (1) (Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial) est une étude randomisée en double aveugle dans laquelle l'efficacité du lisinopril, de l'amlodipine et de la chlortalidone ont été comparées.